Laser Hair Removal in Belem Brazil
Unwanted hair in various body parts may impair ones quality of life. Men and women often feel embraced and uncomfortable having extra hair. It also affects self-confidence and personal relationships. Laser hair removal is relatively a new technique allowing effective, gentle and rapid hair removal. Each person has about 5 million hair follicles, they have different distribution, texture and color, all this factors should be taken under consideration when deciding to use laser hair removal technique. The ideal candidates for this procedure are people with light skin and dark hair. For those people fewer treatments are required to get better results. Dark and coarse hair absorbs energy most effectively; red or blond hair is very difficult to remove. Tanned people with light hair and tanned people with dark hair cannot be treated with usual laser they need a specialized laser technique. People with very dark pigmented skin also cannot be treated using a laser this because they absorb too much energy.
Contraindications for laser hair removal include people with underlying endocrine disorder, people with chronic or active herpes need antiviral treatment before the removal, patients with a history of hyperthrophic scarring, patients taking photosensitizing drugs. Patients with tattoos in the selected areas for hair removal should be informed that laser might change the appearance of the tattoos.
The idea behind hair removal is to destroy hair follicle and thus to prevent future hair growth. Laser is a wave of light energy targeted at specific sites. The wavelength varies; this allows targeting the wave energy specifically to hair follicles sparing the surrounding tissue. This method is called selective photodermolysis. All areas of the body with unwanted hair except around the eyes may be treated. Usually several treatment required to achieve maximal results, this is due to the fact that hair growth in a cyclic matter and laser energy affects only the growing hair. A minimum of 5 treatments usually required each of them 1-3 month apart. Complications of this procedure include skin blistering, skin changes hyper or hypopigmentation, scarring and thrombophlebitis. People with dark skin are more prone to develop the above side effects.
Immediately after the procedure ice packs are given to reduce swelling. Corticosteroid cream may also be applied. Minor skin damage can be treated with topical antibiotics cream. The response to treatment is highly individual; therefore it is difficult to predict the outcome for each patient
More Belem info...
Belem Eat
A?a?: soup-like dessert made from the A?a? fruit.
Mani?oba: stew with pork and meat in a gravy made from manioc leaves (looks strange but tastes delicious).
Pato no Tucup?: duck with jamb? (vegetable) cooked in tucup?.
Tacac?: soup with tucup?, dried shrimps and jamb?.
Regional Ice Creams: made with fruits like A?a?, Cupua??, Tapereb?, Bacur?, etc. Best ice cream maker is Sorveteria Cair?. -
Belem Understand
Bel?m is on the banks of the Bay of Guajar?, which is formed by a set of islands and river mouths on the estuary of the Amazon river. Its river port helps putting into motion the Northern region of Brazil.
The city was established in 1616, after the construction of "Forte do Pres?pio", today "Forte Castelo", at the banks the Par? river. Bel?m is, in a way, a synthesis of the culture and the history of Par? and the Amazon.
-
Plastic Surgery News...
- Pfizer Inc and Nektar Therapeutics have announced that clinical trials of inhaled insulin Exubera® found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product. Pfizer had announced in October 2007 that it would stop marketing Exubera for commercial reasons. In a letter to healthcare professional in the US regarding updated safety information in the drug labelling, Pfizer has stated that there have been 6 newly diagnosed cases of primary lung malignancies in clinical trials among 4740 Exubera-treated patients, and 1 newly diagnosed case among 4292 comparator treated patients. There has also been 1 post-marketing report of a primary lung malignancy in an Exubera-treated patient. It adds that there were too few cases to determine whether the emergence of these events was related to Exubera and all patients who were diagnosed with lung cancer had a prior history of cigarette smoking. The warning in the label stemmed from an ongoing review of data from the Exubera clinical trial programme and post-marketing experience by Pfizer and the FDA. As some people continue to use Exubera, including those enrolled in extended transition programmes or clinical trials, and because of limited availability of Exubera, Pfizer is working closely with patients and their physicians to ensure the continued orderly transition to alternative therapies.
Earlier in the year, Eli Lilly ended its Phase III AIR inhaled insulin programme for type 1 and type 2 diabetes, and Novo Nordisk also recently announced that it was halting development of its AERx inhaled insulin product. The MannKind Corp in the US is continuing its development of its Technosphere Insulin programme, which is in phase III trials.
- New clinical data from a phase II study confirms the competitive profile of Orexo's product OX17 in GERD patients, i.e. fast, effective and sustained inhibition of gastric acid production, a prerequisite for effective symptom relief in the patient. The result demonstrates the clinical potential of OX17 and is an important step in the development of a competitive product.